Amantadine is a medication with dual uses, serving both as an antiviral agent and as a treatment for Parkinson's disease. In the antiviral context, amantadine is primarily employed to inhibit the replication of influenza A viruses. It works by blocking the M2 ion channel protein, preventing the release of viral RNA into host cells. This antiviral property has made amantadine a part of influenza prevention and treatment strategies. In neurology, amantadine finds application in the treatment of Parkinson's disease. Although the precise mechanism of its action in this context remains incompletely elucidated, it is thought to influence dopamine release and receptor sensitivity in the brain. This modulation is believed to alleviate certain symptoms associated with Parkinson's disease, including tremors and bradykinesia. Side effects of amantadine include nausea, dizziness, and insomnia. In the case of prolonged use, patients may develop resistance to its antiviral effects. However, its role in managing Parkinson's disease has established amantadine as a valuable component of the therapeutic arsenal for neurologists.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain